Ipsen improves 2020 targets in confident investor update; CEO dismisses 'less French' concerns

12 May 2017

French drugmaker Ipsen (Euronext: IPN) expects its annual sales to exceed 2.5 billion euros ($2.7 billion) in 2020, an increase of around 58% on its 2016 total of 1.58 billion euros.

The company’s focus on growth through further mergers and acquisitions activity was apparent at an investor day held in London on Thursday, when the improved 2020 financial targets were revealed to reflect recently-acquired assets.

"We are benefiting from a growing focus in oncology, which already represents almost 1 billion euros in sales, and from increasing geographical diversification, with a strengthening presence in the USA"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK